Reviewing multi-site clinical trials with care
Multi-site clinical trials bring together hospitals, universities, research institutes, clinicians, and community partners. That scale can produce stronger evidence and improve access to new treatments, yet it also creates ethical and operational questions that must be addressed before recruitment begins.
At Brisbane Diamantina Health Partners, ethics and governance review supports the responsible translation of research into practice. The process considers whether a study is scientifically sound, ethically acceptable, operationally ready, and appropriate for each participating health service and community.
How Our Ethics and Governance Committee Reviews Multi-Site Clinical Trials is therefore broader than checking a protocol against a standard checklist. It involves coordinated assessment of risk, participant welfare, local capability, data protection, consent, and the practical conditions required for safe delivery.
Why multi-site review matters
A multi-centre study may follow one master protocol while operating across hospitals with different patient populations, facilities, staffing arrangements, electronic records, and referral pathways. A treatment that is suitable for one site may require additional safeguards or logistical planning at another.
The committee examines whether the proposed research question is important and whether the methods can answer it reliably. Poorly designed research can expose participants to inconvenience or risk without generating useful knowledge, so scientific validity is part of ethical review rather than a separate concern.
The review also considers fairness. Recruitment should avoid placing an excessive burden on a particular community, while eligibility criteria should be justified and understandable. Where appropriate, investigators are expected to plan for culturally safe engagement, accessible information, and support for people who may need interpreters or additional assistance.
How the committee assesses the study
The protocol is reviewed alongside the investigator brochure, participant information and consent materials, recruitment documents, safety plans, funding details, and evidence of researcher training. The committee considers the balance between foreseeable risks and potential benefits, including physical, psychological, social, financial, and privacy-related harms.
Special attention is given to vulnerable participants, such as children, people with impaired decision-making capacity, patients experiencing acute illness, and communities affected by social disadvantage. Consent must be voluntary, informed, and proportionate to the participant’s circumstances. It should be an ongoing process rather than a single signature collected at enrolment.
The committee also asks how adverse events, protocol deviations, complaints, and unexpected findings will be identified and reported. Clear escalation pathways help protect participants and allow the study team, sponsor, health service, and ethics body to respond consistently when circumstances change.
Coordinating ethics and site governance
Ethics approval addresses whether the research is ethically acceptable. Governance review addresses whether a particular organisation can safely and practically conduct it. These processes are connected, but they answer different questions and may involve separate documentation and approvals.
For every participating site, governance reviewers may assess contracts, indemnity and insurance arrangements, budgets, pharmacy requirements, pathology and imaging capacity, workforce availability, training, data access, and local policies. They also verify that the principal investigator and supporting teams have the expertise, time, and facilities required by the protocol.
A central ethics review can reduce duplication across jurisdictions, but it does not remove the need for local oversight. Site-specific considerations remain important, especially where the study involves emergency care, Aboriginal and Torres Strait Islander communities, rural or regional services, or complex links between clinical and research systems.
| Review area | Key question | Evidence commonly considered |
|---|---|---|
| Scientific merit | Can the study answer a meaningful question? | Protocol, statistical plan, literature and feasibility evidence |
| Participant welfare | Are risks minimised and benefits fairly represented? | Risk assessment, consent materials and safety monitoring plan |
| Local capability | Can each site deliver the protocol safely? | Staff credentials, facilities, training and service approvals |
| Privacy and data | Will information be collected, stored and shared appropriately? | Data management plan, access controls and retention arrangements |
| Equity and inclusion | Are recruitment and participation fair and accessible? | Eligibility criteria, community engagement and support arrangements |
| Ongoing oversight | How will changes and incidents be managed? | Reporting pathways, monitoring schedule and amendment process |
Protecting consent, privacy and participant safety
Consent documents should explain the purpose of the trial, what participation involves, foreseeable risks, possible benefits, alternatives to participation, costs, compensation, confidentiality arrangements, and the right to withdraw. The committee looks for plain language and checks that important limitations are not obscured by technical detail.
Privacy review extends beyond removing names from a dataset. Investigators must explain who can access information, where it will be stored, how long it will be retained, whether it will leave Australia, and whether it may be used in future research. Genetic, imaging, audio, and linked administrative data may need additional explanation because they can carry a higher risk of re-identification.
Digital tools and predictive models receive careful scrutiny when they influence clinical decisions. Research involving artificial intelligence in cancer research should describe the data used to develop and validate the model, its known limitations, possible bias, and the role of human oversight. Participants need to understand whether an algorithm is investigational and how its output may affect their care.
Applying specialist and community perspectives
Ethics review is strengthened when it reflects the setting in which research will occur. A study involving trauma patients may need to account for pain, distress, fluctuating capacity, urgent treatment, family involvement, and the possibility that participation could reactivate traumatic experiences.
These issues are especially relevant when designing trauma-informed emergency research. Investigators should show how staff will approach potential participants respectfully, avoid unnecessary repetition of distressing information, and provide a meaningful opportunity to decline without affecting clinical care.
Research themes such as cancer, chronic disease, mental health, maternal and child health, and trauma care may each present distinct ethical questions. Community representatives, consumer partners, clinicians, methodologists, and privacy specialists can help identify concerns that may not be visible from the protocol alone.
Preparing a complete and workable submission
A well-prepared submission allows reviewers to focus on the substance of the study rather than resolving avoidable inconsistencies. The protocol, consent form, recruitment materials, registry entry, contracts, and site documents should describe the same intervention, visit schedule, risks, outcomes, and participant commitments.
Investigators can strengthen their application by:
- Mapping every study procedure to its potential risk and mitigation strategy.
- Preparing site-specific documents early, including budgets, contracts, training records, and local contacts.
- Testing participant information materials with consumers for clarity, accessibility, and cultural appropriateness.
- Defining processes for safety reporting, privacy breaches, protocol changes, and withdrawal requests.
- Building realistic time for committee questions, amendments, governance checks, and site activation into the study schedule.
Review is an iterative process. Questions from the committee are intended to clarify responsibilities, improve safeguards, and ensure that the study can work in real clinical environments. Prompt, complete responses help prevent delays and create a stronger record of how participant welfare has been considered.
Strong governance continues after approval. Approved studies require monitoring, reporting, amendment review, and communication between investigators and participating organisations. New information about a treatment, data security issue, recruitment method, or participant risk may require the study to be reconsidered.
Researchers, health services, and community partners can engage with Brisbane Diamantina Health Partners early to discuss ethics, governance, translation, and site readiness. Early collaboration helps turn a promising research question into a safe, practical, and meaningful multi-site clinical trial.
